Morgan Stanley
PRLD icon

Morgan Stanley’s Prelude Therapeutics PRLD Stock Holding History

Morgan Stanley’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.1M Sell
322,161
-12,755
-4% -$33.4K ﹤0.01% 5093
2025
Q4 		$971K Buy
334,916
+50,713
+18% +$85.6K ﹤0.01% 5199
2025
Q3 		$409K Sell
284,203
-179
-0.1% -$179 ﹤0.01% 5595
2025
Q2 		$230K Sell
284,382
-18,397
-6% -$15.9K ﹤0.01% 5797
2025
Q1 		$233K Sell
302,779
-62,380
-17% -$58.2K ﹤0.01% 5670
2024
Q4 		$466K Buy
365,159
+41,470
+13% +$55K ﹤0.01% 5443
2024
Q3 		$670K Buy
323,689
+36,335
+13% +$168K ﹤0.01% 5261
2024
Q2 		$1.09M Sell
287,354
-8,851
-3% -$36K ﹤0.01% 4902
2024
Q1 		$1.4M Sell
296,205
-301,387
-50% -$1.17M ﹤0.01% 4780
2023
Q4 		$2.55M Buy
597,592
+353,122
+144% +$1.08M ﹤0.01% 4785
2023
Q3 		$755K Buy
244,470
+49,144
+25% +$184K ﹤0.01% 4956
2023
Q2 		$879K Buy
195,326
+53,664
+38% +$321K ﹤0.01% 4909
2023
Q1 		$807K Buy
141,662
+51,713
+57% +$315K ﹤0.01% 4979
2022
Q4 		$543K Sell
89,949
-87,839
-49% -$563K ﹤0.01% 5200
2022
Q3 		$1.18M Sell
177,788
-303,000
-63% -$2.04M ﹤0.01% 4789
2022
Q2 		$2.51M Sell
480,788
-65,687
-12% -$334K ﹤0.01% 4357
2022
Q1 		$3.77M Sell
546,475
-299,239
-35% -$2.74M ﹤0.01% 3983
2021
Q4 		$10.5M Buy
845,714
+88,927
+12% +$1.45M ﹤0.01% 2899
2021
Q3 		$23.6M Buy
756,787
+624,622
+473% +$20.2M ﹤0.01% 1914
2021
Q2 		$3.78M Buy
132,165
+108,091
+449% +$3.85M ﹤0.01% 4074
2021
Q1 		$1.04M Sell
24,074
-3,054
-11% -$203K ﹤0.01% 4708
2020
Q4 		$1.94M Buy
27,128
+13,973
+106% +$695K ﹤0.01% 4183
2020
Q3 		$396K Buy
+13,155
New +$371K ﹤0.01% 4754

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Morgan Stanley's PRLD Position: Q1 2026 in Review

Morgan Stanley reduced its Prelude Therapeutics (PRLD) stake by 3.8% in Q1 2026, selling an estimated $33.4K and leaving 322,161 shares worth $1.1M. The position accounts for ﹤0.01% of the portfolio, ranked #5093.

Morgan Stanley first reported a position in PRLD in Q3 2020 and has held it in 23 quarters since. The position peaked at $23.6M in Q3 2021. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

  • Morgan Stanley held 322,161 shares of Prelude Therapeutics worth $1.1M as of Q1 2026.
  • Morgan Stanley sold 12,755 Prelude Therapeutics shares in Q1 2026, an estimated $33.4K.
  • Prelude Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #5093 holding.
  • Morgan Stanley first reported a position in Prelude Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • Morgan Stanley's Prelude Therapeutics position peaked at $23.6M in Q3 2021.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.